Literature DB >> 16682711

Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.

Alison L Bailey1, Steven R Steinhubl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16682711      PMCID： PMC1455414          DOI： 10.1503/cmaj.060288

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.

Authors:  R P Giugliano; C H McCabe; E M Antman; C P Cannon; F Van de Werf; R G Wilcox; E Braunwald
Journal:  Am Heart J       Date:  2001-05       Impact factor: 4.749

2.  Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.

Authors:  John W Eikelboom; Daniel J Quinlan; Shamir R Mehta; Alexander G Turpie; Ian B Menown; Salim Yusuf
Journal:  Circulation       Date:  2005-12-12       Impact factor: 29.690

3.  Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.

Authors:  Marc S Sabatine; David A Morrow; Gilles Montalescot; Mikael Dellborg; Jose L Leiva-Pons; Matyas Keltai; Sabina A Murphy; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Journal:  Circulation       Date:  2005-11-15       Impact factor: 29.690

4.  Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.

Authors:  Paul W Armstrong; Wei-Ching Chang; Lars Wallentin; Patrick Goldstein; Christopher B Granger; Kris Bogaerts; Thierry Danays; Frans Van de Werf
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

5.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.

Authors: 
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

6.  Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.

Authors:  L Wallentin; P Goldstein; P W Armstrong; C B Granger; A A J Adgey; H R Arntz; K Bogaerts; T Danays; B Lindahl; M Mäkijärvi; F Verheugt; F Van de Werf
Journal:  Circulation       Date:  2003-07-07       Impact factor: 29.690

7.  Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.

Authors:  Elliott M Antman; David A Morrow; Carolyn H McCabe; Sabina A Murphy; Mikhail Ruda; Zygmunt Sadowski; Andrzej Budaj; Jose L López-Sendón; Sema Guneri; Frank Jiang; Harvey D White; Keith A A Fox; Eugene Braunwald
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

8.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Authors:  James J Ferguson; Robert M Califf; Elliott M Antman; Marc Cohen; Cindy L Grines; Shaun Goodman; Dean J Kereiakes; Anatoly Langer; Kenneth W Mahaffey; Christopher C Nessel; Paul W Armstrong; Alvaro Avezum; Phil Aylward; Richard C Becker; Luigi Biasucci; Steven Borzak; Jacques Col; Marty J Frey; Ed Fry; Dietrich C Gulba; Sema Guneri; Enrique Gurfinkel; Robert Harrington; Judith S Hochman; Neal S Kleiman; Martin B Leon; Jose Luis Lopez-Sendon; Carl J Pepine; Witold Ruzyllo; Steven R Steinhubl; Paul S Teirstein; Luis Toro-Figueroa; Harvey White
Journal:  JAMA       Date:  2004-07-07       Impact factor: 56.272
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.